Anti-LY6H/ NMLY6 monoclonal antibody

Anti-LY6H/ NMLY6 antibody for FACS & in-vivo assay

Target products collectionGo to LY6H/LY6H products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0780-Ab-1/ GM-Tg-hg-MP0780-Ab-2Anti-Human LY6H monoclonal antibodyHuman
GM-Tg-rg-MP0780-Ab-1/ GM-Tg-rg-MP0780-Ab-2Anti-Rat LY6H monoclonal antibodyRat
GM-Tg-mg-MP0780-Ab-1/ GM-Tg-mg-MP0780-Ab-2Anti-Mouse LY6H monoclonal antibodyMouse
GM-Tg-cynog-MP0780-Ab-1/ GM-Tg-cynog-MP0780-Ab-2Anti-Cynomolgus/ Rhesus macaque LY6H monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0780-Ab-1/ GM-Tg-felg-MP0780-Ab-2Anti-Feline LY6H monoclonal antibodyFeline
GM-Tg-cang-MP0780-Ab-1/ GM-Tg-cang-MP0780-Ab-2Anti-Canine LY6H monoclonal antibodyCanine
GM-Tg-bovg-MP0780-Ab-1/ GM-Tg-bovg-MP0780-Ab-2Anti-Bovine LY6H monoclonal antibodyBovine
GM-Tg-equg-MP0780-Ab-1/ GM-Tg-equg-MP0780-Ab-2Anti-Equine LY6H monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0780-Ab-1/ GM-Tg-hg-MP0780-Ab-2; GM-Tg-rg-MP0780-Ab-1/ GM-Tg-rg-MP0780-Ab-2;
GM-Tg-mg-MP0780-Ab-1/ GM-Tg-mg-MP0780-Ab-2; GM-Tg-cynog-MP0780-Ab-1/ GM-Tg-cynog-MP0780-Ab-2;
GM-Tg-felg-MP0780-Ab-1/ GM-Tg-felg-MP0780-Ab-2; GM-Tg-cang-MP0780-Ab-1/ GM-Tg-cang-MP0780-Ab-2;
GM-Tg-bovg-MP0780-Ab-1/ GM-Tg-bovg-MP0780-Ab-2; GM-Tg-equg-MP0780-Ab-1/ GM-Tg-equg-MP0780-Ab-2
Products NameAnti-LY6H monoclonal antibody
Formatmab
Target NameLY6H
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LY6H benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LY6H/ NMLY6 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0780
    Target NameLY6H
    Gene ID4062,23934,706994,101087968,618749,100066141
    Gene Symbol and SynonymsLY6H,NMLY6
    Uniprot AccessionO94772,A0JNB3
    Uniprot Entry NameLY6H_HUMAN,LY6H_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000176956
    Target ClassificationN/A

    The target: LY6H, gene name: LY6H, also named as NMLY6. Predicted to enable acetylcholine receptor binding activity and acetylcholine receptor inhibitor activity. Predicted to be involved in acetylcholine receptor signaling pathway. Predicted to be located in extracellular region. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.